Navigation Links
Westaim announces 2007 year-end results
Date:2/15/2008

) (134) (99)

Non-controlling interest (806) 466 1,293 3,222

-------------------------------------------------------------------------

Income (loss) from

continuing operations

before income taxes 1,311 (2,276) (2,686) (12,909)

Income tax (expense) recovery (142) 76 (144) 48

-------------------------------------------------------------------------

Income (loss) from continuing

operations 1,169 (2,200) (2,830) (12,861)

Loss from discontinued

operations net of income

taxes (27,976) (8,819) (55,203) (37,696)

-------------------------------------------------------------------------

Net loss $ (26,807) $ (11,019) $ (58,033) $ (50,557)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Income (loss) per common share

Continuing operations

- basic and diluted $ 0.01 $ (0.02) $ (0.03) $ (0.14)

Net loss - basic and

diluted (0.28) (0.12) (0.62) (0.54)

Weighted average number of

common shares outstanding

(thousands) 94,136 93,797 94,070 93,523

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Consolidated Statements of

Comprehensive Loss

Net loss for the period $ (26,807) $ (11,019) $ (58,033) $ (50,557)

Unrealized (loss) gain on

translation of net foreign

operations (145) 103 (1,103) (173)

-------------------------------------------------------------------------

Compre
'/>"/>

SOURCE Westaim Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Fourth Quarter Results
2. Westaim reduces ABCP exposure
3. Westaim announces 2007 third quarter results
4. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Third Quarter Results
5. The Westaim Corporation update on status of short-term investments
6. Abbott Announces 10.8 Percent Increase in Quarterly Dividend
7. China Holdings Announces Starwood Research Institute Initiates Research Coverage
8. Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Have Been Filed Against American Dental Partners, Inc.
9. Hillenbrand Announces Mailing of Proxy Regarding Changing of Company Name in Conjunction with Planned Separation
10. Nerites Corporation Announces Closing of Series A Funding Round
11. Concentric Medical Names Kimberly Bridges as Vice President of Sales, Announces Receipt of $15 Million Growth Funding
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Studies show dramatic decline in rheumatoid vasculitis in US veterans 55469 1Studies show dramatic decline in rheumatoid vasculitis in US veterans 55469 2Discovery of natural odors could help develop mosquito repellents 13710 1Discovery of natural odors could help develop mosquito repellents 13710 2Discovery of natural odors could help develop mosquito repellents 13710 3Senator Ted Kennedy 3A A Member of the NAMI Family 55466 1Senator Ted Kennedy 3A A Member of the NAMI Family 55466 2